XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. 
View this email in your browser


2017 is off to a great start for us all at XenoGesis. The recently opened, state-of-the-art bioanalysis and metabolic identification suite is up and running, and our attention is now focused on finding someone to spearhead our business development, more on that later in the newsletter.

Our 2017 events schedule is already looking busy. This month we have been to BioEurope Spring in Barcelona and then Copenhagen for the Medicon Valley Alliance event on drug formulation and bioavailability. We have another webinar planned in May with our friends at Juniper Pharma Services, more details to follow nearer the time.

In a move to further develop our expertise and knowledge of the impact that potential new medicines can have in man from a toxicity point of view, XenoGesis has joined the British Toxicology Society and will be attending the BTS Annual Congress in Liverpool on the 3rd - 5th April. You can read more about this here.

We are also delighted to have been shortlisted as a Medilink UK Business Awards finalist for the Outstanding Achievement category. The awards ceremony takes place next month at the Med-Tech Innovation EXPO in Coventry.

And finally, a huge well done to Graham Trevitt (XenoGesis' answer to Michael Phelps) who raised over £500 for Comic Relief by swimming the distance of the English Channel! It isn't too late to show your support and make a donation.

As always, we welcome your feedback.

Warm regards
Richard Weaver and the team at XenoGesis

Team news

Expansion continues with creation of new role to drive business development

XenoGesis is always interested to speak to talented individuals about working with us. We have developed a new role to spearhead business development as we enter our next stage of growth.
If you know of anyone that might be interested in this exciting opportunity, please do let us know or forward this on to them. 

Read more 


Solving poor solubility

40% of marketed drugs have poor solubility, and of more concern, this rises to 80% of compounds entering development at this current time. This is an issue we see all the time, and we work closely with Juniper Pharma Services to help understand and overcome solubility problems, saving our clients time and money, whilst increasing their chances of success.

Read more
Partner news

Combined PK/PD support and expertise

Integrating in vitro and in vivo data into the optimal design of pharmacokinetics / pharmacodynamics (PK/PD) studies improves the likelihood of success and adds knowledge to the project, creating a compelling package for partners and stakeholders. The derived PK/PD relationships can also be used in predictions of efficacious human dose.

XenoGesis works in collaboration with Axis BioServices to bring together combined PK/PD support and expertise to client projects.

Read more
Copyright © 2017 XenoGesis Ltd, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp